Close Menu

More articles about Sponsors

The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.

The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.

Agilent, which co-led Mission Bio's 2018 $30 million Series B financing round, will comarket the Tapestri platform to cancer researchers in North America.

The two UK companies are validating GeneFirst's assay for use with Rapid Dx's Rapid Minilab RT-PCR Desktop Point of Care Platform.

With $2.5 million in initial philanthropy funding, the consortium plans to launch several research projects and establish a data commons for storing and sharing results. 

As part of the deal, Applied DNA will permanently place robotic and diagnostic equipment at the hospital to enable validation of the test.

The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.

Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.

With the help of Bionano Genomics, Genoox, Rescale, and Amazon, the investigators aim to study 1,000 patients with SARS-CoV-2 to better understand the disease.

The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.

The researchers identified specific macrophage and conventional dendritic cell subsets as key mediators of cellular crosstalk in the tumor microenvironment.

A new paper outlines an upcoming effort to trace tumor development and trajectory in time and space using single-cell genetics and other genomic methods.

The team also found that the proportion of infected people didn't change substantially during the screening period, consistent with beneficial containment.

Tumors from patients who underwent full surgical resection had distinct molecular profiles from those treated with neoadjuvant chemotherapy.

Both studies emerged from the ongoing Human Cell Atlas project and could help scientists decide on the best approaches to use in various contexts.

Exposure to DNA-damaging cancer treatments affects mutational signatures found in advanced and metastatic cancers, with alterations possibly indicating drug resistance.

The study suggests that pediatric low-grade gliomas driven by genetic rearrangements tend to be diagnosed earlier and have better outcomes than those driven by SNVs.

The researchers said a functional investigation of the virus' unknown transcripts and RNA modifications will elucidate its life cycle and pathogenicity.

Combining questionnaire-derived phenotyping with hospital diagnoses increases the power to tease out genetic associations within biobank data.

The protein-protein interactions tallied in the project are expected to inform future studies of biology and disease in various tissue and cell types.

Pages

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.